Selig Group Announces Acquisition of Performance Systematix
5.1.2021 16:30:00 EET | Business Wire | Press release
Selig Group (“Selig”), owned by CC Industries (“CCI”), announced today that it has completed an acquisition of Performance Systematix (“PSI”). Founded in 1984, PSI is the leading supplier of container and packaging venting solutions worldwide, which protect container integrity, eliminate waste, and reduce shipping costs. The combination provides Selig with highly complementary adjacent capabilities to serve its customers more broadly on a global basis. This transaction is Selig’s third acquisition and reflects its strategy to augment growth and expand its business model via complementary solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210105005048/en/
“PSI is an exceptional company with a long history of growth, and has built its success on solving customers’ problems, a core value that Selig shares,” said Bill Crown, President and Chief Executive Officer of CCI. “We look forward to supporting both Selig and PSI’s continued growth globally and further expanding the combined company’s capabilities and solutions.”
Steve Cassidy, President and Chief Executive Officer of Selig added, “PSI’s culture of innovation, service and quality are well-aligned with Selig and will enable us to serve customers better as a combined organization with expanded capabilities and short, highly responsive product development cycles.”
Glenn Dunn, PSI’s President stated, “Selig is an ideal partner to support PSI’s team in its next phase of growth. This is a highly strategic combination which expands both companies’ product lines, enabling us to provide a more comprehensive solutions offering for customers globally. We will continue to focus on the innovative, high quality products and the exemplary service our customers rely upon.”
PSI will operate as a subsidiary of Selig and continue serving its customers from its Grand Rapids, Michigan, USA facility.
About Selig Group (www.seligsealing.com)
Selig Group is a leading global flexible packaging company. The company is the leading global supplier of innovative, technically-differentiated closure lining solutions for food, beverage, pharmaceutical, healthcare, personal care and industrial applications. Selig also manufacturers a range of technical and flexible packaging products in Europe for pouch and other applications. The company’s products are designed to serve customers’ needs for ensuring freshness, extending shelf life, providing tamper evidence, counterfeit deterrence, e-commerce and brand protection. Selig is headquartered in Naperville, Illinois with manufacturing and distribution locations worldwide.
About Performance Systematix (www.psix.com)
PSI is the leading supplier of engineered and vented packaging solutions worldwide. Customers rely on the company’s engineered solutions for applications where packaged products experience off-gassing, pressure changes, temperature changes, or handling variability. Over its history, PSI has grown by developing new solutions and providing reliable and consistent quality and service to customers. The company serves a global customer base from its facility in Grand Rapids, Michigan, USA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005048/en/
Contact information
SELIG GROUP CONTACT
John Brown
jbrown@seligsealing.com
+1 630 615 7240
PERFORMANCE SYSTEMATIX CONTACT
John Grover
jgrover@psix.com
+1 616 949 9090
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 15:29:00 EEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
